Investigación / Grupos de investigación

Grupo  27

Farmacia Hospitalaria y Farmacogenómica

Publicaciones (413)

  • Amor-Garcia, MA; Rodriguez-Gonzalez, CG; Chamorro-de-Vega, E; Herranz-Alonso, A; Sanjurjo-Saez, M.

    Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid

    ANNALS OF PHARMACOTHERAPY. 2022; 56(4): 401-411 Nº de citas: 7 [doi:10.1177/10600280211038504]

  • Hoyo-Munoz, A; Collado-Borrell, R; Escudero-Vilaplana, V; Bastos-Oreiro, M; Herranz-Alonso, A; Sanjurjo-Saez, M.

    Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease

    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2022; 47(4): 548-551 Nº de citas: 3 [doi:10.1111/jcpt.13513]

  • Diaz-Navarro, M; Hafian, R; Manzano, I; Perez-Granda, MJ; Cercenado, E; Pascual, C; Rodriguez, C; Munoz, P; Guembe, M.

    A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing

    Infectious Diseases and Therapy. 2022; 11(2): 743-755 Nº de citas: 6 [doi:10.1007/s40121-021-00579-4]

  • Butragueno-Laiseca, L; Martin, GM; Cortes, RG; Galan, CR; de Marigorta, ZMDM; Anton, JG; Nunez, AR; Fernandez-Llamazares, CM; Manrique-Rodriguez, S; Cid, JLH.

    Multicenter randomized clinical trial comparing dexamethasone versus placebo in preventing upper airway obstruction after extubation in critically ill children

    Scientific Reports. 2022; 12(1): Nº de citas: 9 [doi:10.1038/s41598-022-08178-0]

  • Romero-Jimenez, R; Escudero-Vilaplana, V; Chamorro-de-Vega, E; Ais-Larisgoitia, A; Matilla, MEL; Herranz-Alonso, A; Sanjurjo, M.

    The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search

    JOURNAL OF MEDICAL INTERNET RESEARCH. 2022; 24(3): Nº de citas: 5 [doi:10.2196/31016]

  • Tejerina, F; Catalan, P; Rodriguez-Grande, C; Adan, J; Rodriguez-Gonzalez, C; Munoz, P; Aldamiz, T; Diez, C; Perez, L; Fanciulli, C; de Viedma, DG; Gregorio Maranon Microbiol ID COVI.

    Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

    BMC INFECTIOUS DISEASES. 2022; 22(1): Nº de citas: 89 [doi:10.1186/s12879-022-07153-4]

  • Garcia-Moreno, FJ; Escobar-Castellanos, M; Maranon, R; Rivas-Garcia, A; Manrique-Rodriguez, S; Mora-Capin, A; Fernandez-Llamazares, CM.

    Adecuacy of pediatric antimicrobial prescribing in the Emergency Department at discharge

    ANALES DE PEDIATRIA. 2022; 96(3): 179-189 Nº de citas: 6 [doi:10.1016/j.anpedi.2020.11.019]

  • García-Moreno FJ; Escobar-Castellanos M; Marañón R; Rivas-García A; Manrique-Rodríguez S; Mora-Capín A; Fernández-Llamazares CM.

    Adecuacy of pediatric antimicrobial prescribing in the Emergency Department at discharge.

    Anales De Pediatria. 2022; 96(3): 179-189 [doi:10.1016/j.anpede.2020.11.015]

  • Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

    Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical & Translational Oncology. 2022; 24(3): 483-494 Nº de citas: 37 [doi:10.1007/s12094-021-02708-4]

  • Narrillos-Moraza, A; Gomez-Martinez-Sagrera, P; Amor-Garcia, MA; Escudero-Vilaplana, V; Collado-Borrell, R; Villanueva-Bueno, C; Gomez-Centurion, I; Herranz-Alonso, A; Sanjurjo-Saez, M.

    Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale

    JMIR mHealth and uHealth. 2022; 10(2): Nº de citas: 20 [doi:10.2196/32826]

  • Villanueva-Bueno C; Montecatine-Alonso E; Jiménez-Parrilla F; Fernández-Llamazares CM; Manrique-Rodríguez S; Zamora-Flores E; Dolz E; Fernández-Polo A; Catillo-Salinas F; Comuñas J; Gallego-Fernández C; González-López M; Gómez-Trevecedo Calvo MT; Gázquez-Pérez R; Álvarez Del Vayo-Benito C; Gil-Navarro MV.

    Antimicrobial defined daily dose in neonatal population.

    Enfermedades Infecciosas Y Microbiologia Clinica (english Ed.). 2022; 40(2): 59-65 [doi:10.1016/j.eimce.2021.05.012]

  • Enriquez-Gomez, A; Ortega-Navarro, C; Fernandez-Cordon, C; Diez-Villanueva, P; Martinez-Selles, M; de Lorenzo-Pinto, A; de Miguel-Yanes, JM.

    Comparison of a polypharmacy-based scale with Charlson comorbidity index to predict 6-month mortality in chronic complex patients after an ED visit

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2022; 88(4): 1795-1803 Nº de citas: 3 [doi:10.1111/bcp.15096]

  • Vicente-Valor, J; Garcia-Gonzalez, X; Ibanez-Garcia, S; Duran-Garcia, ME; de Lorenzo-Pinto, A; Rodriguez-Gonzalez, C; Mendez-Fernandez, I; Percovich-Hualpa, JC; Herranz-Alonso, A; Sanjurjo-Saez, M.

    PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

    BIOMEDICINE & PHARMACOTHERAPY. 2022; 146: 112519-112519 Nº de citas: 21 [doi:10.1016/j.biopha.2021.112519]

  • Villanueva-Bueno, C; Montecatine-Alonso, E; Jimenez-Parrilla, F; Fernandez-Llamazares, CM; Manrique-Rodriguez, S; Zamora-Flores, E; Dolz, E; Fernandez-Polo, A; Catillo-Salinas, F; Comunas, J; Gallego-Fernandez, C; Gonzalez-Lopez, M; Calvo, MTGT; Gazquez-Perez, R; del Vayo-Benito, CA; Gil-Navarro, MV; Paediat Antimicrobial Defined Dail.

    Antimicrobial defined daily dose in neonatal population

    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2022; 40(2): 59-65 Nº de citas: 7 [doi:10.1016/j.eimc.2021.05.007]

  • Gil-Manso, S; Blanco, IM; Lopez-Esteban, R; Carbonell, D; Lopez-Fernandez, LA; West, L; Correa-Rocha, R; Pion, M.

    Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals

    Frontiers in Immunology. 2022; 12: 793142-793142 Nº de citas: 18 [doi:10.3389/fimmu.2021.793142]

  • Villanueva-Bueno, C; Escudero-Vilaplana, V; Collado-Borrell, R; Gimenez-Manzorro, A; Ribed, A; Marzal-Alfaro, B; Revuelta-Herrero, JL; Gonzalez-Haba, E; Herranz, A; Sanjurjo, M.

    Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion On Drug Safety. 2022; 21(1): 107-119 Nº de citas: 5 [doi:10.1080/14740338.2021.1965990]

  • Gomez-Centurion, I; Oarbeascoa, G; Garcia, MC; Fresnena, MCL; Carreno, MJM; Vilaplana, VE; Gonzalez-Haba, E; Bailen, R; Dorado, N; Juarez, LM; Macias, GR; Lopez, PF; Encinas, C; Bastos-Oreiro, M; Anguita, J; Sanjurjo, M; Diez-Martin, JL; Kwon, M.

    Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

    INTERNATIONAL JOURNAL OF HEMATOLOGY. 2022; 115(1): 61-68 Nº de citas: 15 [doi:10.1007/s12185-021-03219-2]

  • Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

    Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

    Expert Opinion on Drug Metabolism & Toxicology. 2022; 17(12): 1467-1473 Nº de citas: 10 [doi:10.1080/17425255.2021.2027908]